Skip to content

Aripiprazole versus risperidone for treatment of autism

Aripiprazole versus risperidone for treatment of autism

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201110233930N15
Enrollment
50
Registered
2011-12-12
Start date
2011-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pervasive developmental disorders. Childhood autism

Interventions

Intervention 1: aripiperazole (2-15mg/day). Intervention 2: risperidone (0.5-3mg/day).
Treatment - Drugs
aripiperazole (2-15mg/day)
risperidone (0.5-3mg/day)

Sponsors

Vice chancellor for research, Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: DSM-IV diagnosis of autism spectrum disorders; both genders; being able to eat medication; providing written informed consent. Exclusion Criteria: unstable medical condition; evidence of active liver disease; unstable hypertension or cardiac disease; unstable asthma; and kidney disease as determined by the investigator; subjects who are allergic to the medications; initiation of new behavioral therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Abbrant Behavior Checklis. Timepoint: every 4 week. Method of measurement: interview.

Secondary

MeasureTime frame
Adverse effects. Timepoint: every 4 week. Method of measurement: interview.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026